<SEC-DOCUMENT>0001140361-23-022852.txt : 20230504
<SEC-HEADER>0001140361-23-022852.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504073022
ACCESSION NUMBER:		0001140361-23-022852
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		23886479

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc20052467_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:insm="http://insmed.com/20230504" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_ab6d6d14e14a4c53bc2b03e33a409453" contextRef="c20230504to20230504" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_abcfa4cbda4c47f2ae70d6d252922f1f" contextRef="c20230504to20230504">0001104506</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_a5a82d29a507455aaea8e3bd5406bcd5" contextRef="c20230504to20230504">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="insm-20230504.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230504to20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div><span style="font-size: 14pt;"> </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_ac5b31cee0a449c980dca3b6aee11567" contextRef="c20230504to20230504">8-K</ix:nonNumeric></div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">The Securities Exchange Act of 1934</div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_efbb2940f462422e9d71fadb81fcc1c6" contextRef="c20230504to20230504" format="ixt:date-monthname-day-year-en">May 4, 2023</ix:nonNumeric></div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_0803787190de4376b36e60235c6501fa" contextRef="c20230504to20230504">INSMED INCORPORATED</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact name of registrant as specified in its charter)</div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 31.99%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_cb0a7bd9c97e4f85913144c91d1c4c9b" contextRef="c20230504to20230504" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 31.99%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_190a2d471a6449c6b204e10d31a165f5" contextRef="c20230504to20230504">000-30739</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_ecea5c601ae54b77a5448a2f733d5500" contextRef="c20230504to20230504">54-1972729</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 31.99%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(State or other jurisdiction of incorporation)</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 31.99%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Commission File Number)</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_79b464edea5c4b2bb4bf69b55a378701" contextRef="c20230504to20230504">700 US Highway 202/206</ix:nonNumeric><br />
              </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_20df8a324f0f4617be56dcb0829cf8da" contextRef="c20230504to20230504">Bridgewater</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_12b5ef32428449a49bde64775748f57b" contextRef="c20230504to20230504" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_bbe017af9fb34e30a53fdef3bbd7b391" contextRef="c20230504to20230504">08807</ix:nonNumeric><br />
              </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Zip Code)</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Address of principal executive offices)</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>


</table>
      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_fd2b2cfc0a67468f9e01485f9f9e69e2" contextRef="c20230504to20230504">908</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_510413dded9a442ca1c2568fd8bdd88a" contextRef="c20230504to20230504">977-9900</ix:nonNumeric></span></div>

      <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not Applicable</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Former name or former address, if changed since last report.)</div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions (see General Instruction A.2. below):</div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_76c0376040f1480793b512e53d7ae09c" contextRef="c20230504to20230504" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_2ab08bf0e29644cdab96054ae53408ef" contextRef="c20230504to20230504" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_db72a46c8f7647039d4ad95e0babfbae" contextRef="c20230504to20230504" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_218971837ed54212bbd8b9dcbcce47ee" contextRef="c20230504to20230504" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 37.64%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 37.54%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Name of each exchange on which</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 37.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_c3616ce948db4a279d88645b818bfdca" contextRef="c20230504to20230504">Common Stock, par value $0.01 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 24%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_aaaa75a221154072b2ffa3fed0052807" contextRef="c20230504to20230504">INSM</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 37.54%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><span style="-sec-ix-hidden:Fact_a5a82d29a507455aaea8e3bd5406bcd5">Nasdaq Global Select Market</span><br />
              </div>
            </td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the
        Securities Exchange Act of 1934 (17 CFR 240.12b-2).</div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_080b4340fbef40729a4db3610664284e" contextRef="c20230504to20230504" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div style="font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ITEM 2.02 &#8211; Results of Operations and Financial Condition.</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">On May 4, 2023, Insmed Incorporated issued a press release regarding its financial results for the three months ended March 31, 2023. A copy of this press release is
        furnished herewith as Exhibit 99.1 pursuant to this Item 2.02.</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as
        amended, except as shall be expressly set forth by specific reference in such a filing.</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ITEM 9.01 - Financial Statements and Exhibits.</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(d) <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Exhibits</span></span></div>

      <div style="font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 13.5%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">No.</div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 85%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 13.5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';"><a href="brhc20052467_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 85%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Press release issued by Insmed Incorporated on May 4, 2023.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 13.5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">104</div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 85%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Cover Page Interactive Date File (embedded within the Inline XBRL document).</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">SIGNATURES</span></div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned hereunto duly authorized.</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 59.66%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Dated: May 4, 2023</div>
            </td>

    <td colspan="2" style="vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">INSMED INCORPORATED</div>
            </td>

  </tr>

  <tr>

    <td style="width: 59.66%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 59.66%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">By:</div>
            </td>

    <td style="width: 34.64%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman';">/s/ Michael A. Smith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 59.66%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
            </td>

    <td style="width: 34.64%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Michael A. Smith</div>
            </td>

  </tr>

  <tr>

    <td style="width: 59.66%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
            </td>

    <td style="width: 34.64%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">General Counsel and Corporate Secretary</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br />
      </div>

      <div style="font-size: 10pt;">
<div>&#160;
        </div>
<hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc20052467_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 99.1</div>
      <div>&#160;</div>
      <div style="text-align: left;"><img src="image00003.jpg"></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Insmed Reports First Quarter 2023 Financial Results and Provides Business Update</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212;Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter
        of 2024&#8212;</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212;Company to Provide Detailed Update on Early-Stage Research Programs on May 8, 2023&#8212;</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212;Company on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (amikacin liposome inhalation suspension) in Third
        Quarter of 2023&#8212;</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212;ARIKAYCE Total Revenue of $65.2 Million for the First Quarter of 2023, Reflecting 23% Annual Growth Over the First Quarter of 2022&#8212;</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">&#8212;Company Reaffirms Full-Year 2023 Guidance for Global ARIKAYCE Revenues of Between $285 Million and $300 Million&#8212;</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">BRIDGEWATER, N.J., May 4, 2023 /PRNewswire/ &#8212; Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with
        serious and rare diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Insmed began 2023 with solid momentum, demonstrated by a strong quarter of global revenues from our commercial business and continued execution of our clinical
        development pipeline of mid-to-late-stage assets,&#8221; commented Will Lewis, Chair and Chief Executive Officer of Insmed. &#8220;In the first quarter, we achieved our goal of enrollment completion of adult patients in the Phase 3 ASPEN trial. The pace of
        enrollment and widespread geographic reach of this study speak to the global enthusiasm for this program as well as the tireless efforts of the Insmed teams that facilitated this significant accomplishment. In parallel, we also continue to advance
        our early-stage research efforts. I am tremendously excited to debut several components of our early-stage platforms at our upcoming research day, including the indications, development candidates, proprietary technologies, and preclinical data to
        support our efforts. Importantly, the event will also allow us to showcase some of the Insmed team leaders who are driving innovation in the treatment of serious and rare diseases.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Recent Pillar Highlights</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Pillar 1: ARIKAYCE</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z18f25d86afd34400881b54f8733de375" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">ARIKAYCE global revenue grew 23% in the first quarter of 2023 compared with the first quarter of 2022, reflecting strong performance in the U.S., as well as the ongoing launches in
                Japan and Europe.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z57f04fd68c794ffc8d1f36c230bbf63f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Insmed continues to advance the post-marketing, confirmatory trial program for ARIKAYCE, consisting of the ARISE and ENCORE trials in patients with newly diagnosed or recurrent <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Mycobacterium avium </font>complex (MAC) lung infection who have not started antibiotics. Insmed continues to anticipate sharing topline efficacy and safety
                data from the ARISE study in the third quarter of 2023 and completing enrollment in the ENCORE study by the end of 2023.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Pillar 2: Brensocatib</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z29bcfec5d5994f49a0f3a3dfb3d1e3f6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Enrollment has been completed in over 1,700 adult patients across nearly 40 countries in the pivotal ASPEN study, a global Phase 3 trial designed to assess the efficacy, safety,
                and tolerability of brensocatib in bronchiectasis. Insmed continues to expect the topline data readout from the ASPEN study in the second quarter of 2024.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z16227f61a1c94646953be0478c4cfcdf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Baseline characteristics for evaluable adult patients enrolled in the ASPEN study were made available this morning and can be found at <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>https://investor.insmed.com/download/ASPEN_Baseline.pdf</u></font>. The preliminary comparison to the respective baseline characteristics from the Phase 2 WILLOW study demonstrates a broadly similar baseline profile
                for participants in both studies across key metrics.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z2de5b08507f34dd0aee547d229bb1cef" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Due to the rapid enrollment of ASPEN, Insmed expects the pace of enrollment of its planned Phase 2 study of brensocatib in patients with chronic rhinosinusitis without nasal polyps
                (CRSsNP) to be stronger than previously expected. For that reason, Insmed has chosen to adjust the initiation timing of the CRSsNP study from mid-2023 to the fourth quarter of 2023, which has the added benefit of reducing near-term cash
                deployment.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Pillar 3: TPIP</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z95b1e612ff8543b9b33daccdd5250ed1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Insmed is currently enrolling a Phase 2 study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary hypertension associated with interstitial lung disease
                (PH-ILD) and a Phase 2 study in patients with pulmonary arterial hypertension (PAH).</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="za268f2bb4aeb4b128a697348b9c3adda" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">The Company continues to anticipate sharing interim, blinded dose titration and safety and tolerability data from both the PH-ILD and PAH studies in the second half of 2023,
                pending the rate of enrollment. Topline results from the PH-ILD study are on track to be shared in the first half of 2024.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Pillar 4: Early-Stage Research</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zba2e7f40c1e84458898af306dd824e16" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">On May 8, 2023, Insmed plans to provide a detailed update on its early-stage research portfolio, encompassing artificial intelligence (AI)-driven protein engineering, gene therapy,
                and protein manufacturing. The Company will provide an in-depth introduction to several of its early-stage programs as well as the experts leading each of these research engines. The event, titled &#8220;The Future of Rare at Insmed: Functional
                Genes, AI-Enhanced Proteins, Glowing Algae, and More,&#8221; will be held in New York and will also be webcast live.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z0c1b738e781140de82791272f5dd28b3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">As previously shared, Insmed anticipates having at least six investigational new drug (IND) applications filed from this portfolio by the end of 2025.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf0e2e57eef0a48bd999bb0e4ce03bc64" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">The Company expects to initiate a Phase 1/2 study of its first gene therapy candidate in the second half of 2023 and anticipates sharing early clinical data from that program in
                the first half of 2024.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Corporate Updates</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8ccc1139eae047578416372c9077f768" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">In April 2023, Insmed appointed Makoto Nakamura to the role of General Manager in Japan, where he will oversee commercial operations for ARIKAYCE and support the preparation of
                potential future product launches in the country. Mr. Nakamura has extensive experience leading commercial divisions in Japan for global pharmaceutical companies including Gilead Sciences and Pfizer, Inc.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">First Quarter 2023 Financial Results</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc121282f451c43d586f2b4f953ca462d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Total revenue for the first quarter ended March 31, 2023, was $65.2 million, reflecting 23% year-over-year growth compared to total revenue of $53.1 million for the first quarter
                of 2022.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z85ac33679af84b44abf34f08af5d1a62" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Total revenue for the first quarter of 2023 was comprised of ARIKAYCE net sales of $49.1 million in the U.S., $13.2 million in Japan, and $3.0 million in Europe and rest of world,
                reflecting 20% and 23% year-over-year growth in the U.S. and Japan, respectively.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zedccda7c7fd24444a446a5a7796e6ebc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Cost of product revenues (excluding amortization of intangibles) was $13.8 million for the first quarter of 2023, compared to $12.2 million for the first quarter of 2022.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z802b82c4021d47709e0221dcd243eba8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Research and development (R&amp;D) expenses were $127.9 million for the first quarter of 2023, compared to $84.4 million for the first quarter of 2022 and $124.8 million for the
                fourth quarter of 2022. The increase in R&amp;D expenses compared to fourth-quarter 2022 was driven by a non-cash charge of $10.3 million related to the acquisition of Vertuis Bio, Inc. in January 2023.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb44b22a8d80f499ba433f13200bc1df4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Selling, general and administrative (SG&amp;A) expenses for the first quarter of 2023 were $79.9 million, compared to $56.7 million for the first quarter of 2022 and $73.5 million
                for the fourth quarter of 2022. The modest increase in SG&amp;A expenses compared to fourth-quarter 2022 primarily reflects additional investments in launch readiness activities.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6beec6b89d714a57af5ff8c867d1d150" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Insmed reported a net loss of $159.8 million, or $1.17 per share, for the first quarter of 2023, compared to a net loss of $94.6 million, or $0.80 per share, for the first quarter
                of 2022, and a net loss of $160.1 million, or $1.21 per share, for the fourth quarter of 2022.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Balance Sheet, Financial Guidance, and Planned Investments</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z85f7fc40e1984b569f194fc73af0e31f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">As of March 31, 2023, Insmed had cash, cash equivalents, and marketable securities totaling $999 million, down from $1.15 billion as of December 31, 2022. Higher cash burn in
                first-quarter 2023 was primarily driven by items that are not expected to recur in the remaining quarters of 2023, such as the annual employee incentive compensation payout.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z750f092ca85a4674b57b2ea7494389a5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Insmed continues to expect full-year 2023 global revenues for ARIKAYCE to be between $285 million and $300 million.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zfd61a267d7d74b62a6fc26f2d9c2451c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Insmed continues to anticipate that over 80% of total expenditures will be on its mid-to-late stage and commercial programs (ARIKAYCE, brensocatib, and TPIP), and that less than
                20% of overall spend will be on its early-stage research programs, reflecting the Company&#8217;s historical approach to spending.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z902bf92c3e0243879bc1a09fb1d1276e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">The Company plans to invest in the following key activities in 2023:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zbef32343dbdd4ad0a2ba5deb3d4318a1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">commercialization and expansion of ARIKAYCE globally;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z84acf5221ab940529a848d2abc872b9e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">advancement of brensocatib, including the Phase 3 ASPEN study in patients with bronchiectasis and commercial launch readiness activities, as well as development across additional
                neutrophil-mediated diseases;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z556a79df665241bc941569aca27956f1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(iii)</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">advancement of the clinical trial program for ARIKAYCE (ARISE and ENCORE), which is intended to satisfy the post-marketing requirement for full approval of its current indication
                and potentially support label expansion to include all patients with a MAC lung infection;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6e235bbe568d4022ab2ff97a2b120b27" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(iv)</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">advancement of its Phase 2 clinical development programs for TPIP; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z9fca6f05a48b4f8c8a5ba1b62f3b45b3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(v)</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">development of its early-stage research platforms.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Conference Call</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;">Insmed will host a conference call beginning today at 8:30 AM Eastern Time. Shareholders
          and other interested parties may participate in the conference call by dialing (833) 470-1428 (U.S.) or (929) 526-1599 (international) and referencing access code 468531. The call will also be webcast live on the Company&#8217;s website at </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>www.insmed.com</u></font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;">.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;">A replay of the conference call will be accessible approximately 30 minutes after its
          completion through June 3, 2023, by dialing (866) 813-9403 (U.S.) or (+44) 204-525-0658 (international) and referencing access code 281829. A webcast of the call will also be archived for 90 days under the Investor Relations section of the
          Company&#8217;s website at </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>www.insmed.com</u></font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;">.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">INSMED INCORPORATED</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated Statements of Net Loss</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(in thousands, except per share data)</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(unaudited)</div>
        <div style="text-align: center; font-size: 10pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="za20baccea9f549759ffb1511c80415bf" class="cfttable">

            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Three Months Ended</div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31,</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
                <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"> 2023</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
                <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">2022</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Product revenues, net</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">65,214</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">53,107</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Operating expenses:</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Cost of product revenues (excluding amortization of intangible assets)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">13,830</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">12,191</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Research and development</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">127,865</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">84,356</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Selling, general and administrative</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">79,914</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">56,748</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Amortization of intangible assets</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,263</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,263</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Change in fair value of deferred and contingent consideration liabilities</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(9,500</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(11,618</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Total operating expenses</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">213,372</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">142,940</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Operating loss</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(148,158</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(89,833</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Investment income</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">10,524</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">137</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Interest expense</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(20,003</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(3,291</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Change in fair value of interest rate swap</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(1,533</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">-</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Other expense, net</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(111</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(1,249</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Loss before income taxes</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(159,281</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(94,236</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Provision for income taxes</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">483</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">385</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Net loss</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(159,764</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(94,621</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Basic and diluted net loss per share</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(1.17</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(0.80</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Weighted average basic and diluted common shares outstanding</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">136,355</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">118,929</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left;">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">INSMED INCORPORATED</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated Balance Sheets</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(in thousands, except par value and share data)</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z598ac113d52f4494a16f64fe3c2e45e4" class="cfttable">

            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2023</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December 31, 2022</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="2">
                <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(unaudited)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Assets</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Current assets:</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt;" colspan="2">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Cash and cash equivalents</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">968,907</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,074,036</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Marketable securities</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">29,774</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">74,244</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Accounts receivable</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">30,523</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">29,713</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Inventory</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">71,317</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">69,922</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Prepaid expenses and other current assets</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">28,542</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">25,468</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Total current assets</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,129,063</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,273,383</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Fixed assets, net</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">59,556</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">56,491</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Finance lease right-of-use assets</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">23,019</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">23,697</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Operating lease right-of-use assets</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">21,154</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">21,894</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Intangibles, net</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">67,493</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">68,756</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Goodwill</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">136,110</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">136,110</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Other assets</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">81,322</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">76,104</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Total assets</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,517,717</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,656,435</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-weight: bold;">Liabilities and shareholders' equity</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Current liabilities:</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Accounts payable and accrued liabilities</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">179,005</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">182,117</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Finance lease liabilities</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">2,158</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,217</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Operating lease liabilities</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">6,821</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">6,909</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Total current liabilities</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">187,984</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">190,243</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Debt, long-term</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,132,188</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,125,250</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Royalty financing agreement</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">150,173</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">148,015</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Contingent consideration</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">38,600</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">51,100</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Finance lease liabilities, long-term</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">29,015</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">29,636</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Operating lease liabilities, long-term</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">14,534</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">14,853</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Other long-term liabilities</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">9,876</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">9,387</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Total liabilities</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,562,370</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,568,484</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Shareholders' equity:</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Common stock, $0.01 par value; 500,000,000 authorized shares,<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> 136,429,216</font> and 136,653,731 issued and outstanding shares at March 31, 2023 and December 31, 2022, respectively</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,364</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,357</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Additional paid-in capital</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">2,809,242</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">2,782,416</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Accumulated deficit</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(2,856,342</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(2,696,578</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Accumulated other comprehensive income</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,083</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">756</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Total shareholders' (deficit) equity</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">(44,653</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">
                <div style="font-family: 'Times New Roman';">)</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftcurrcell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">87,951</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;">
                <div style="text-align: left; text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Total liabilities and shareholders' equity</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,517,717</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftguttercell">&#160;</td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftcurrcell">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftnumcell">
                <div style="font-family: 'Times New Roman';">1,656,435</div>
              </td>
              <td valign="bottom" nowrap="nowrap" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-size: 10pt;" colspan="1" class="cftfncell">&#160;</td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About ARIKAYCE</div>
      <div>&#160;</div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;">ARIKAYCE is approved in the United States as ARIKAYCE</font><sup style="color: #323237; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE</font><sup style="color: #323237; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;"> Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE</font><sup style="color: #323237; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;"> inhalation 590 mg (amikacin sulfate
            inhalation drug product).</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;">Current international treatment guidelines recommend the use
            of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and
            kidney function. Insmed&#8217;s proprietary PULMOVANCE</font><sup style="color: #323237; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;"> liposomal technology enables the delivery of amikacin directly to the
            lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira</font><sup style="color: #323237; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;"> Nebulizer System manufactured by PARI Pharma GmbH (PARI).</font></div>
        <div>&#160;</div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About PARI Pharma and the Lamira<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Nebulizer System</div>
      <div>
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">ARIKAYCE is delivered by a novel inhalation device, the Lamira<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Nebulizer System, developed by PARI. Lamira<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a quiet, portable nebulizer that
          enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI&#8217;s 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve
          patient care.</div>
        <div><br>
        </div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Brensocatib</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis
        and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of
        white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and
        inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Brensocatib is an investigational drug product that has not been approved for any indication
        in any jurisdiction.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About TPIP</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Treprostinil palmitil inhalation powder (TPIP) is a dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil
        linked by an ester bond to a 16-carbon chain. Developed entirely in Insmed&#8217;s laboratories, TPIP is a potentially highly differentiated prostanoid being evaluated for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary
        disorders. TPIP is administered in a capsule-based inhalation device. TPIP is an investigational drug product that has not been approved for any indication in any jurisdiction.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.</div>
      <div>&#160;</div>
      <div style="border: 1px solid #000000; padding: 5px; width: 99%;">
        <div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS</div>
          <div>&#160;</div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARIKAYCE has been associated with an increased risk of respiratory adverse reactions, including hypersensitivity pneumonitis, hemoptysis,
            bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases.</div>
        </div>
      </div>
      <div> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Hypersensitivity Pneumonitis </font>has been reported with the use of ARIKAYCE in the
          clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen
          (3.1%) compared to patients treated with a background regimen alone (0%). Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity pneumonitis occurs,
          discontinue ARIKAYCE and manage patients as medically appropriate<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font></div>
        <div>&#160;</div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Hemoptysis </font>has been reported with the use of ARIKAYCE in the clinical trials.
          Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). If<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>hemoptysis occurs, manage patients as medically appropriate<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font></div>
        <div>&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Bronchospasm</font> has been reported with the use of ARIKAYCE in the clinical trials.
          Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen
          (28.7%)<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>compared to patients treated with a background regimen alone (10.7%). If bronchospasm occurs during the use of ARIKAYCE, treat patients as medically
          appropriate<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font></div>
        <div>&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exacerbations of underlying pulmonary disease</font> has been reported with the use of
          ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease (reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis) have been reported at a higher
          frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients treated with background regimen alone (9.8%)<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font> If
          exacerbations of underlying pulmonary disease occur during the use of ARIKAYCE, treat patients as medically appropriate<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font></div>
        <div>&#160;</div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Anaphylaxis and Hypersensitivity Reactions:</font> Serious and potentially
          life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients taking ARIKAYCE. Signs and symptoms include acute onset of skin and mucosal tissue hypersensitivity reactions (hives, itching, flushing, swollen
          lips/tongue/uvula), respiratory difficulty (shortness of breath, wheezing, stridor, cough), gastrointestinal symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and symptoms of anaphylaxis (tachycardia, low
          blood pressure, syncope, incontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate for previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or a hypersensitivity reaction occurs, discontinue ARIKAYCE and
          institute appropriate supportive measures.</div>
        <div>&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Ototoxicity </font>has been reported with the use of ARIKAYCE in the clinical trials.
          Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and vertigo) were reported with a higher frequency in patients treated with ARIKAYCE plus background regimen (17%) compared to patients treated with background regimen<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>alone (9.8%). This was primarily driven by tinnitus (7.6% in ARIKAYCE plus background regimen vs 0.9% in the background regimen alone arm) and dizziness (6.3%
          in ARIKAYCE plus background regimen vs 2.7% in the background regimen alone arm).<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">&#160;</font>Closely monitor patients with known or suspected auditory or vestibular
          dysfunction during treatment with ARIKAYCE. If ototoxicity occurs, manage patients as medically appropriate, including potentially discontinuing ARIKAYCE.</div>
        <div>&#160;</div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Nephrotoxicity</font> was observed during the clinical trials of ARIKAYCE in patients
          with MAC lung disease but not at a higher frequency than background regimen alone. Nephrotoxicity has been associated with the aminoglycosides. Close monitoring of patients with known or suspected renal dysfunction may be needed when prescribing
          ARIKAYCE.</div>
        <div>&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Neuromuscular Blockade</font>: Patients with neuromuscular disorders were not enrolled
          in ARIKAYCE clinical trials. Patients with known or suspected neuromuscular disorders, such as myasthenia gravis, should be closely monitored since aminoglycosides may aggravate muscle weakness by blocking the release of acetylcholine at
          neuromuscular junctions.</div>
        <div>&#160;</div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Embryo-Fetal Toxicity</font>:<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides, including ARIKAYCE, may be associated with total, irreversible, bilateral congenital deafness in pediatric patients
          exposed <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">in utero</font>. Patients who use ARIKAYCE during pregnancy, or become pregnant while taking ARIKAYCE should be apprised of the potential hazard to the
          fetus.</div>
        <div>&#160;</div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Contraindications</font>: ARIKAYCE is contraindicated in patients with known
          hypersensitivity to any aminoglycoside.</div>
        <div>&#160;</div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Most Common Adverse Reactions</font>: The most common adverse reactions in Trial 1 at
          an incidence &#8805;5% for patients using ARIKAYCE plus background regimen compared to patients treated with background regimen alone were dysphonia (47% vs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis (18% vs 13%), ototoxicity (17%
          vs 10%), upper airway irritation (17% vs 2%), musculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs 10%), exacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10% vs 8%),
          headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%), change in sputum (5% vs 1%), and chest discomfort (5% vs 3%).</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Drug Interactions</font>: Avoid concomitant use of ARIKAYCE with medications associated
        with neurotoxicity, nephrotoxicity, and ototoxicity. Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. Avoid concomitant use of ARIKAYCE with ethacrynic acid, furosemide, urea, or
        intravenous mannitol.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Overdosage</font>: Adverse reactions specifically associated with overdose of ARIKAYCE
        have not been identified. <font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Acute toxicity should be treated with immediate withdrawal of ARIKAYCE, and baseline tests of renal function should be undertaken.
          Hemodialysis may be helpful in removing amikacin from the body. In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment.</font></div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">U.S. INDICATION</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">LIMITED POPULATION: ARIKAYCE<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is indicated in adults, who have limited or no alternative treatment options, for the treatment of <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Mycobacterium avium</font> complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6
        consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">. </font>This drug is indicated for use in a limited and specific population of patients.</div>
      <div>&#160;</div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum
          cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">.</font></div>
        <div>&#160;</div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"><u>Limitation of Use</u>: </font>ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background
        regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.</div>
      <div>
        <div>&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Patients are encouraged to report negative side effects of prescription drugs to the FDA.
            Visit </font><font style="color: rgb(0, 0, 0);"><u><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">www.fda.gov/medwatch</font></u></font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">, or call 1&#8209;800&#8209;FDA&#8209;1088. You can also call the Company at 1-844-4-INSMED.</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;">Please see </font><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Full Prescribing Information</u></font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #323237;">.</font></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Insmed</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first
        commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of
        serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%9%%%-->
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-looking Statements</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">This press release contains forward-looking statements that involve substantial risks and uncertainties. &#8220;Forward-looking statements,&#8221; as that term is
        defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221;
        &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking
        statements.</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The forward-looking statements in this press release are based upon the Company&#8217;s current expectations and beliefs, and involve known and unknown risks,
        uncertainties and other factors, which may cause the Company&#8217;s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected,
        anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S., Europe or
        Japan, or for the Company&#8217;s product candidates in the U.S., Europe, Japan or other markets, including separate regulatory approval for the Lamira<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Nebulizer System in each market and for each usage; failure to successfully commercialize
        ARIKAYCE, the Company's only approved product, in the U.S., Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain U.S., European
        or Japanese approval for ARIKAYCE; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; impact of the COVID-19 pandemic and efforts to reduce its spread on the Company&#8217;s
        business, employees, including key personnel, patients, partners and suppliers;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>risk that brensocatib or TPIP does not prove to be effective or safe for
        patients in ongoing and future clinical studies, including, for brensocatib, the ASPEN study;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>uncertainties in the degree of market acceptance of ARIKAYCE by
        physicians, patients, third-party payors and others in the healthcare community; the Company&#8217;s inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that the Company will not successfully or in
        a timely manner complete the study to validate a patient reported outcome tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE; inability of the Company, PARI or the Company&#8217;s other third-party
        manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Nebulizer System; the Company&#8217;s inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices
        for ARIKAYCE; development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib, TPIP or the Company&#8217;s other product candidates; inaccuracies in the Company&#8217;s estimates of the size of the potential markets for ARIKAYCE,
        brensocatib, TPIP or the Company&#8217;s other product candidates or in data the Company has used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the risks
        and uncertainties associated with, and the perceived benefits of, the Company&#8217;s secured senior loan with certain funds managed by Pharmakon Advisors, LP and the Company&#8217;s royalty financing with OrbiMed Royalty &amp; Credit Opportunities IV, LP,
        including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the perceived impact of the restrictions on the Company&#8217;s operations under these agreements; the Company&#8217;s
        inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of the Company&#8217;s product candidates that are approved in the future;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>risk that the Company&#8217;s competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product the Company is developing for a particular indication;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and the Company&#8217;s other product candidates due to the Company&#8217;s limited experience in conducting preclinical
        development activities and clinical trials necessary for regulatory approval and its potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other
        things;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>risks that the Company&#8217;s clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third
        parties on which the Company is dependent to manufacture sufficient quantities of ARIKAYCE or the Company&#8217;s product candidates for commercial or clinical needs, to conduct the Company&#8217;s clinical trials, or to comply with the Company&#8217;s agreements or
        laws and regulations that impact the Company&#8217;s business or agreements with the Company;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>the Company&#8217;s inability to attract and retain key personnel or to
        effectively manage the Company&#8217;s growth; the Company&#8217;s inability to successfully integrate its recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities; risks that the Company&#8217;s
        acquired technologies, products and product candidates are not commercially successful; the Company&#8217;s inability to adapt to its highly competitive and changing environment;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>risk that the Company is unable to maintain its significant customers; risk that government healthcare reform materially increases the Company&#8217;s costs and damages its financial condition; deterioration in general economic
        conditions in the U.S., Europe, Japan and globally, including the effect of prolonged periods of inflation, affecting the Company, its suppliers, third-party service providers and potential partners; the Company&#8217;s inability to adequately protect
        its intellectual property rights or prevent disclosure of its trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters; restrictions or other obligations imposed on the
        Company by agreements related to ARIKAYCE or the Company&#8217;s product candidates, including its license agreements with PARI and AstraZeneca AB, and failure of the Company to comply with its obligations under such agreements; the cost and potential
        reputational damage resulting from litigation to which the Company is or may become a party, including product liability claims; risk that the Company&#8217;s operations are subject to a material disruption in the event of a cybersecurity attack or
        issue; business disruptions or expenses related to the upgrade to the Company&#8217;s enterprise resource planning system; the Company&#8217;s limited experience operating internationally; changes in laws and regulations applicable to the Company&#8217;s business,
        including any pricing reform, and failure to comply with such laws and regulations; the Company&#8217;s history of operating losses, and the possibility that the Company may never achieve or maintain profitability; goodwill impairment charges affecting
        the Company&#8217;s results of operations and financial condition; inability to repay the Company&#8217;s existing indebtedness and uncertainties with respect to the Company&#8217;s ability to access future capital; and delays in the execution of plans to build out
        an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company&#8217;s forward-looking statements because, by
        their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect
        the Company&#8217;s business, please see the factors discussed in Item 1A, &#8220;Risk Factors,&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent Company filings with the Securities and Exchange Commission
        (SEC).</div>
      <div>&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release.
        The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any
        such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: right;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contact:</div>
      <div>&#160;</div>
      <div>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Investors:</div>
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Bryan Dunn</div>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Executive Director, Investor Relations</div>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Insmed</div>
        <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(646) 812-4030</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>bryan.dunn@insmed.com</u></div>
        <div><br>
        </div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Eleanor Barisser</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Associate Director, Investor Relations</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Insmed</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(718) 594-5332</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>eleanor.barisser@insmed.com</u></div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Media:</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Mandy Fahey</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Executive Director, Corporate Communications</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Insmed</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(732) 718-3621</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>amanda.fahey@insmed.com</u></div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <div style="text-align: right;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>insm-20230504.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<xs:schema targetNamespace="http://insmed.com/20230504" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:insm="http://insmed.com/20230504" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20230504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="insm-20230504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://insmed.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>insm-20230504_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>insm-20230504_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://insmed.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="insm-20230504.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://insmed.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  O 'H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZHHK!\:>*
M=/\ !^BMJ>K>:8-ZQJD2[G=CT R0/7J:T-)U2TU73;.^LY0UO=QB2(M\I8$>
MA[U7*^7FMH!4NO$>G6WB&WT:65A?3KN1=IQ]"?4X-4?B+XK3P9X9EU62V:Z*
MNL:1JVW+,>Y["JUIXBTS5/%][I]M8L=6L8G5+F2,8XQD ]0,G^=0>&H=4U&'
M48/%MN);!QRET@VYSSC/:JJ6I5(1E%Z[G)1Q'/)ZW5WMTMW-7P!XF3Q?X7M=
M72UDM?-+*T;G."IP2#W'O715Q/B9=:M+G3K?PQ"(]/5 %6W0; <]#V"XQ^M=
MJN=HW=<<UDZBE.2BK)'1&IS2<4MA:***984444 %%%% !1110 4444 >1_%W
MQI?Z%)-:ZEX1@U+02R!+FXD^1W(SC&#@@Y_*NLL]'A\16/AS60S6:K:PS+;1
M?=4%0P4'MCI]*Y3]IC_D0;?_ *_4_DU4/''AMM2^$>CZS'JE]:2:;H\+K!$^
M(Y?W:]1Z^]=CHTZM&"EI=^8I0C-6D>RK;PQS/,D4:RO]YPH!;ZFLWQ3HJ^(-
M#N-.>>2W6;'[Q.2,'/XBO!?AQX6U[X@>%XUO]=NK#1+-FB@6++--)G+,W(SC
M.*W/@;>:GI/CSQ!X3OKZ6[M+17*;R2 ZN!D9Z9!Y%-X=TVY1E[T13I1G%PDM
M&>Q^'M*31-%M=/CE>9;=-N]^IYS6BI##*D$>U> ?$359O$/Q<'A?5]:FT;08
M54923RQ(Q0-DGIDDX!/ Q72^"_A[=>&_'QNM,O;FY\-RZ>R":6Z#MYK$= .,
M8'!J9T-.><M6K_TQQ@H148[(];H[X[U\K^,--U3P?\4+/3]%U2_O[N78]N;F
M0D^8^0N>QP>>E:_Q&\"ZQX-T6+Q,OBB^NM32=/.8DKAF[J<\\]CVJ_J<;Q7/
M\6VA5CZ1/'6BO!M.\)>(_B?HH\0:YKL]@LJ'[%:0J=@4#&XC(^\1G_(K7_9O
MUK4-0T/5K+4KF2X2PF5(FD;<54@Y7/IQ6<\-RP<E*[6X6/8B<#)X%'4<5\X2
M:S%\2?&>IIKWB0Z-X=LF*V\"3",R\D C/!)QDDYZ@5-X=U3_ (0CXG:;I.A:
M^VL^']2*HR-*)/++$CMP&! /&,@U?U.5K7UM>UOU"Q]$UX-\?+76-!D&N6/B
M/44BO+A8A9HY5(<)V(/?&>G>I_&6LZUXY^(\G@S0;^33M-M01=SQ9#.1][..
M< G:!GK7(_&'X=P^#M$L;N#5KZ],TWE.EP<C."=P]/I^M:X2BH5(\[U?2P(^
MAM+M;MGM+M[LM"T*DQGOE1_7^=;55=)_Y!=G_P!<4_\ 015JO.>XCR3]IC_D
M0;?_ *_4_DU:6O?\F_G_ + </_HM:[+Q-X=TOQ-IZV6M6WVFV5Q($W%?F'0\
M?6I;C1-/N/#_ /8DL&[3?(%MY.X_ZL  #/7H*Z%6BH1CV=QW.)_9\ 'PPL,#
M&9IB?^^S7%^ [NWM/V@?%C7<\4"N9D4R.%#,77 &>_M7M7A_1+#P]I<>GZ1!
MY%I&2RIN+8).3R:Y[4OAEX3U/5)]1O=+$EW/)YLC^:XRWKC-6J\.>HW>TO\
M,+G.^,/^$*\5^,K[P_XEMEM;^Q@1UOVF6$L& ;:&[XW=#GO7$_#DR^'OC+_8
M'AK5I=3T)E8S8?<BC83GCC*MM&X>M>I>*/A=X9\2ZFVH:C;SBZ955GBF*[@H
M"C(]@!6UX4\'Z'X5A=-$L8[=I !)*26=\>K'^54L1"--P5W=;/:_<+GD7CK_
M ).,\.?]L/YFNN_:,_Y)G<?]?,/_ *%77WWA'1;_ ,1VVNW5F'U2WV^5-O8;
M=O3C.*M^(]"T[Q'IC:?K%O\ :+1F5RFXKR#D<BH^L1YZ<OY;!<R/A;_R3;PY
M_P!>$?\ Z#7F7[-EU;1/XEMIKB&.>:Y41QNX#/PV<#J:]MTO3[;2M-MK"QC\
MJUMXQ%$F2=JCH,FN5L?AAX2L=2AO[72@EW#*)D?S7.'!R#C/K2C6ARU(O[0'
MB'PTTGPQ;^,-<T3Q[;VXGCDVV[W+M&H8,<C.1U!!&:]>TOPU\-;36[$:9'I7
M]I^8'MUANV=]PYR &/IWK;\6_#_PYXKE\_5[ -=8"_:(F*28]R.OXU2\-?"[
MPKX>OHKVQL7>[A;?'+-*S%#[=JTJXB-3WG)I]N@7/,/"FIV_ACX_>(5UN1;2
M.\DE5)93M4;F#J23V(J/]H[Q;I^K?V=I&E7,5T+=S/<20L&121A5R.,]37L7
MC'P%X?\ %S1R:S9[KB,;5GB8H^WTR.H^M4H_A=X131UTW^RE:W$@E)+MO=@,
M9+9R?ITJX8FESQJR3NE8+G1>'+^SO](M6L;JWN52)%8PR!]IVC@XZ&M2L3PM
?X6TCPM;3P:':"VBF<22#>6RV,9Y-;=<$K7?+L(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140233564753360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INCORPORATED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">54-1972729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 US Highway 202/206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-9900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INSM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>brhc20052467_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="insm-20230504.xsd" xlink:type="simple"/>
    <context id="c20230504to20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230504to20230504"
      id="Fact_ab6d6d14e14a4c53bc2b03e33a409453">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20230504to20230504"
      id="Fact_abcfa4cbda4c47f2ae70d6d252922f1f">0001104506</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20230504to20230504"
      id="Fact_a5a82d29a507455aaea8e3bd5406bcd5">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20230504to20230504"
      id="Fact_ac5b31cee0a449c980dca3b6aee11567">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230504to20230504"
      id="Fact_efbb2940f462422e9d71fadb81fcc1c6">2023-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20230504to20230504"
      id="Fact_0803787190de4376b36e60235c6501fa">INSMED INCORPORATED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230504to20230504"
      id="Fact_cb0a7bd9c97e4f85913144c91d1c4c9b">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20230504to20230504"
      id="Fact_190a2d471a6449c6b204e10d31a165f5">000-30739</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230504to20230504"
      id="Fact_ecea5c601ae54b77a5448a2f733d5500">54-1972729</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230504to20230504"
      id="Fact_79b464edea5c4b2bb4bf69b55a378701">700 US Highway 202/206</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20230504to20230504"
      id="Fact_20df8a324f0f4617be56dcb0829cf8da">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230504to20230504"
      id="Fact_12b5ef32428449a49bde64775748f57b">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230504to20230504"
      id="Fact_bbe017af9fb34e30a53fdef3bbd7b391">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230504to20230504"
      id="Fact_fd2b2cfc0a67468f9e01485f9f9e69e2">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230504to20230504"
      id="Fact_510413dded9a442ca1c2568fd8bdd88a">977-9900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20230504to20230504"
      id="Fact_76c0376040f1480793b512e53d7ae09c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230504to20230504"
      id="Fact_2ab08bf0e29644cdab96054ae53408ef">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230504to20230504"
      id="Fact_db72a46c8f7647039d4ad95e0babfbae">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230504to20230504"
      id="Fact_218971837ed54212bbd8b9dcbcce47ee">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20230504to20230504"
      id="Fact_c3616ce948db4a279d88645b818bfdca">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230504to20230504"
      id="Fact_aaaa75a221154072b2ffa3fed0052807">INSM</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230504to20230504"
      id="Fact_080b4340fbef40729a4db3610664284e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( ,H[I%8D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #*.Z1699!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ RCND5A5<[4;N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ RCND5IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #*.Z16E#BE$%P$  "9$   &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ RCND5I^@&_"Q
M @  X@P   T              ( !GPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " #*.Z16EXJ[',     3 @  "P              @ %[#P  7W)E;',O
M+G)E;'-02P$"% ,4    " #*.Z16'#AEZC\!   \ @  #P
M@ %D$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ RCND5B0>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ RCND5F60>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc20052467_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://insmed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  brhc20052467_8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="brhc20052467_8k.htm">brhc20052467_8k.htm</File>
    <File>brhc20052467_ex99-1.htm</File>
    <File>insm-20230504.xsd</File>
    <File>insm-20230504_lab.xml</File>
    <File>insm-20230504_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc20052467_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc20052467_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20230504_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20230504_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "insm-20230504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "insm",
   "nsuri": "http://insmed.com/20230504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052467_8k.htm",
      "contextRef": "c20230504to20230504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://insmed.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052467_8k.htm",
      "contextRef": "c20230504to20230504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-23-022852-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-022852-xbrl.zip
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MVO!SV&*$@M17P/3C,$<-7"UWKY!3EA0S@+(@I48=>)0I-7IA,":#Y2>1@!E
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MW7D$J/4S'@%T,W4ZQM1PJ2.I*K(ZR_HT*><L%;SI+E:H.L/+XNGJ2P:V$,[
M'HW=H=GC_2'8LYXW<D:#H6NZ9K_3T/X+HGT="<G[UG&R47VLA2)AUQ\7 MG
M;@Z_FFUSB-U55,Z!<1]]8&GP<:\]J([=:8\Z/QS[1D^1H5.HJSL8= HK.]N!
M9:Z=93WK>"Y!U_?<I]8@EU,A$J/DD\XZ2RKXG>ORH+."DSU&=+;O#3VP2(0Y
M'O7L_F#LF>.>YPR[W.N(KMD4N;TD)G1$I+KLB<XKOERJJS+HOTR AGW%?41+
MA:^JP0UA7HR=9DBX*A<T6OZ_CL<E!02+6E4*!O*Q/K.S]JBT@A/A" S098L
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M-I-%311OD-0S'*V9[W(&S GLDBZ&+X.4NE[CH:$8+)]6Z9K(9 K G$S9/])
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M)>2!>N)+;DN?NF?7QNQ?#^-ZL[V5/=RM1+W>?&_#F]H4X]L?&_U.G?,#[H7
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MHQXOF8?)NM' 3EOZ LX9S]M!;A,3"BW]MCA4T!*^:>V'#$Z8$QB$DIS,'+1
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MY] ?Q5$Q?_.T<[D38A]'!=G-'U!+ P04    " #*.Z16-2?!GW\(  !T6
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M<$;6CWX,7^Q;E5)A&92-"PKT=5M(MB[L!63.%(4C%"B7H$+3AUJQ[RUYT29
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M)3\@?G*^C8@_XB?:G_X'4$L! A0#%     @ RCND5@U0E]JX$0  K'(  !,
M             ( !     &)R:&,R,# U,C0V-U\X:RYH=&U02P$"% ,4
M" #*.Z16W. 0TZE*  "L.@, %P              @ 'I$0  8G)H8S(P,#4R
M-#8W7V5X.3DM,2YH=&U02P$"% ,4    " #*.Z16=,287T0#   S#P  $0
M            @ ''7   :6YS;2TR,#(S,#4P-"YX<V102P$"% ,4    " #*
M.Z16-2?!GW\(  !T6   %0              @ $Z8   :6YS;2TR,#(S,#4P
M-%]L86(N>&UL4$L! A0#%     @ RCND5CFYIL#;!0  [3X  !4
M     ( ![&@  &EN<VTM,C R,S U,#1?<')E+GAM;%!+!08     !0 % $L!
(  #Z;@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
